Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat ...

That has now changed. Pharmaceutical company GlaxoSmithKline (GSK) has begun marketing Jesduvroq (daprodustat), a new hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for patients ...

Tumor vessels with two prolyl hydroxylase (PHD) domain 2 (PHD2) alleles have an abnormal endothelium, are hypoperfused, and cause tumor hypoxia, which fuels tumor-cell invasiveness and metastasis.

Investigators propensity-score matched 546 users of erythropoietin, an erythropoiesis-stimulating agent (ESA), with 546 users of roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor ...

Vafseo, which is part of the hypoxia-inducible factor–prolyl hydroxylase inhibitor (HIF-PHI) branch of meds, was approved last March to treat CKD-associated anemia in patients who have received ...

It does so by preventing the auto-inactivation of lysyl and prolyl hydroxylase – two main enzymes involved in collagen biosynthesis. Collagen also plays a vital role in wound healing.